Search results
Showing 1 to 50 of 8149 results
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Show all sections
Sections for NG51
- Overview
- Could this be sepsis?
- Face to face assessment
- Under 16s: evaluating risk and managing suspected sepsis
- Pregnant or recently pregnant people: evaluating risk and managing suspected sepsis
- Over 16s (not pregnant or recently pregnant): evaluating risk and managing suspected sepsis
- Antibiotic therapy, intravenous fluid and oxygen
- Finding and controlling the source of infection
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.
Details, meeting dates and minutes of the independent technology appraisal committees
Our board meetings are open to the public. You can download the agenda, papers and minutes for each meeting.
Agenda and papers of the NICE public board meeting on 20 March 2024
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management....
Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
NICE research projects and partners.
Resources to help organisations who want to help develop NICE guidance
Take part in the production of medical technologies guidance.
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Find out more about the medical technologies advisory committee members by reading their biographies. Dr Jacob Brown (chair) Biography Jacob
We're bringing our guidance together by topic, so that it's all in one place, clearer to understand and easier to access. We expect that this will...
Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over.
Charging for technology appraisals and highly specialised technologies
Information about charging for our technology appraisal (TA) and highly specialised technologies (HST) assessments.
Changes to charging for Technology Appraisal and Highly Specialised Technologies consultation
Take part in our consultation: 5 proposals about the way the NICE charges for TAs and HSTs.
Charging procedure: technology appraisal and highly specialised technologies evaluations
Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly
Charging procedure: technology appraisal and highly specialised technologies evaluations
Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA
This register shows current declarations of interest made by our: non-executive directors executive team members senior leaders. We publish it
This International Women’s Day, we’re specifically focusing on the invaluable contributions of two of the women who help shape our guidance through their independent / voluntary committee roles. Hear from them, as they talk about their involvement with NICE and what #InspireInclusion means to them.
Our tool to help you plan for and implement NICE guidance. View upcoming guidance and understand the impact of guidance on your resources.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Our board sets out our strategic priorities and policies.
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment. Patient
Information, meeting dates and minutes of the medical technologies advisory committee
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....
NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
We want you to tell us what matters to you, your organisation or your community.
To help us understand the needs of our users we are offering the opportunity to be directly involved in the work we do. Fellows, registrars and...
We're excited that you're interested in joining a committee and helping us improve health and social care services. By joining, you'll have the...
Digital technologies for managing non-specific low back pain: early value assessment (HTE16)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over....
View recommendations for HTE16Show all sections
A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.
Admission rates due to heart failure in people with diabetes
Admission rates due to heart failure in people with diabetes Subject(s): Diabetes Date of publication: 01 August
All our committees include experienced professionals with knowledge of a particular topic within health or social care . Professional members also...
Find out more about being on a committee at NICE.
A public consultation on our new approach to prioritising guidance is now open
Running for 4 weeks, the consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
Support for industry to engage with NICE during all stages of health technology development
Achieving and demonstrating compliance with NICE TA and HST guidance
The NHS and patients need evidence that commissioners are funding medicines and treatments approved through the NICE Technology Appraisal (TA) or...